Abstract: Described is a process for preparing beclomethsaone dipropionate Freon® clathrate comprising the use of an agent which selectively binds methanol to selectively remove methanol from a mixture of methanol and Freon® 11 containing beclomethasone dipropionate.

Abstract: Novel compounds, such as: ##STR1## are disclosed. Also disclosed are methods for inhibiting the abnormal growth of cells, for inhibiting farnesyl protein transferase and for treating cancers using the novel compounds.

Abstract: This invention provides an improved process for producing azetidinones. More particularly, this invention provides the steps of producing an trans-azetidinone represented by the formula ##STR1## from a carboxylic acid R.sup.2 --D--CH.sub.2 COOH, an aldehyde R.sup.1 --A--CHO and an amine RNH.sub.2, by the steps of: (a1) converting a carboxylic acid to the corresponding acid chloride; (b1) deprotonating a chiral oxazolidinone and treating the resulting anion with the product of step (a1); (c1) enolizing the product of step (b1) and condensing with the aldehyde; (d1) hydrolyzing the product of step (c1); (e1) condensing the product of step (d1) with the amine; and (f1) cyclizing the product of step (e1). Alternatively, the process comprises (a2) enolizing the product of step (b1) and condensing, in the presence of a Lewis acid, with a Schiff's base prepared from the aldehyde and the amine; and (b2) cyclizing the product of step (a2).

Abstract: "Novel compounds, such as: ##STR1## are disclosed. Also disclosed are methods for inhibiting the abnormal growth of cells, for inhibiting farnesyl protein transferase and for treating cancers using the novel compounds.

Abstract: Novel compounds of Formula (7.0a), (7.0b) or (7.0c): ##STR1## are disclosed. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering a compound of the formula (7.0a), (7.0b) or (7.0c) to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being.

Abstract: A method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells is disclosed. The method comprises the administration of a compound of Formula 1.0: ##STR1## to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being. Novel compounds of formulas 5.0, 5.1 and 5.2, wherein R is --C(R.sup.20)(R.sup.21)(R.sup.46), and 5.3, 5.3A and 5.3B, wherein R is --N(R.sup.25)(R.sup.48), are disclosed. Also disclosed are processes for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3. Further disclosed are novel compounds which are intermediates in the process for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3.

Abstract: Novel compounds of Formula ##STR1## are disclosed. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering a compound of the above formula to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being.

Abstract: Described is a process for the regioselective dehydration of 11-hydroxy steroids using PCl.sub.5, PCl.sub.3, POCl.sub.3 or either SO.sub.2 Cl.sub.2 and imidazole, or PPh.sub.3 and CCl.sub.4. The disclosed process selectively forms .DELTA..sup.9,11 steroids from either 11-.alpha.- or 11-.beta.-hydroxy steroids, and can also be used for the one-step conversion of 11,21 -dihydroxy steroids to 21-chloro-.DELTA..sup.9,11 steroids. Also disclosed are processes for the regioselective conversion of 11-.beta.-chloro steroids to .DELTA..sup.9,11 steroids, and for regioselectively converting an 11,17,21-trihydroxy streoid to a 21-chloro-11,17-dihydroxy steroid.

Abstract: Materials and methods are described for identifying signal transducing molecules which activate promoters, such as the human c-fos proto-oncogene promoter, as well as antagonists of such molecules. Also described are human c-fos promoter activating proteins, and in particular novel proteins, designated CROC-1 protein and CROC-4 protein, nucleic acids encoding said proteins, and mammalian cells transfected with vectors containing such nucleic acids.

Abstract: A method of inhibiting Ras function and therefore inhibiting cellular growth is disclosed. The method comprises the administration of a compound of Formula. 1.0 ##STR1## Also disclosed are novel compounds of the formulas: ##STR2## Also disclosed are processes for making 3-substituted compounds of the Formulas 1.1, 1.2 and 1.3.Further disclosed are novel compounds which are intermediates in the processes for making the 3-substituted compounds of Formulas 1.1, 1.2, and 1.3.

Abstract: A method of inhibiting Ras function and therefore inhibiting cellular growth is disclosed. The method comprises the administration of a compound of Formula 1.0 ##STR1## Also disclosed are novel compounds of the formulas: ##STR2## Also disclosed are processes for making 3-substituted compounds of the Formulas 1.1, 1.2 and 1.3.Further disclosed are novel compounds which are intermediates in the processes for making the 3-substituted compounds of Formulas 1.1, 1.2, and 1.3.

Abstract: A method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells is disclosed. The method comprises the administration of a compound of Formula 1.0: ##STR1## to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being.Novel compounds of formulas 5.0, 5.1 and 5.2, wherein R is --C(R.sup.20)(R.sup.21)(R.sup.46), and 5.3, 5.3A and 5.3B, wherein R is --N(R.sup.25)(R.sup.48), are disclosed.Also disclosed are processes for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3.Further disclosed are novel compounds which are intermediates in the process for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3.

Abstract: Described is a method for potentiating the effects of chemotherapeutic agents or radiation therapy in mammals afflicted with cancer. The method comprises administering IL-4 in conjunction either with other chemotherapeutic agents or with radiation therapy.

Abstract: A method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells is disclosed. The method comprises the administration of a compound of Formula 1.0: ##STR1## to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being. Novel compounds of formulas 5.0, 5.1 and 5.2, wherein R is --C(R.sup.20)(R.sup.21)(R.sup.46), and 5.3, 5.3A and 5.3B, wherein R is --N(R.sup.25)(R.sup.48), are disclosed. Also disclosed are processes for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3. Further disclosed are novel compounds which are intermediates in the process for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3.

Abstract: A method of inhibiting Ras function and therefore inhibiting cellular growth is disclosed. The method comprises the administration of a novel compound of the formula (Ia), (Ib) or (Ic) ##STR1## wherein: R and R.sup.1 are H, alkyl, halogeno, OH, alkoxy, NH.sub.2, alkylamino, dialkylamino, CF.sub.3, SO.sub.3 H, CO.sub.2 R.sup.3, NO.sub.2, SO.sub.2 NH.sub.2, or CONHR.sup.4 ;n is 0 or 1;R.sup.2 is a group of the formula R.sup.5 C(O)--, R.sup.5 CH.sub.2 C(O)--, R.sup.5 C(R.sup.6).sub.2 C(O)--, R.sup.5 SO.sub.2 --, R.sup.5 CH.sub.2 SO.sub.2 --, R.sup.5 SCH.sub.2 C(O)--, R.sup.5 OC(O)--, R.sup.5 NHC(O)--, R.sup.5 C(O)C(O)-- or R.sup.5 SC(O)--;R.sup.5 is alkyl, aryl, arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl or heterocycloalkyl; andR.sup.6 is alkyl or C(R.sup.6).sub.2 is a carbocyclic ring;or pharmaceutically aceptable salts thereof.

Abstract: Novel compounds of Formula (7.0a), (7.0b) or (7.0c): ##STR1## are disclosed. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering a compound of the formula (7.0a), (7.0b) or (7.0c) to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being.

Abstract: A method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells is disclosed. The method comprises the administration of a compound of Formula 1.0: ##STR1## to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being.Novel compounds of formulas 5.0, 5.1 and 5.2, wherein R is --C(R.sup.20)(R.sup.21)(R.sup.46), and 5.3, 5.3A and 5.3B, wherein R is --N(R.sub.25)(R.sub.48), are disclosed.Also disclosed are processes for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3.Further disclosed are novel compounds which are intermediates in the process for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3.

Abstract: Disclosed are chiral hydrazine derivatives of the formula (Ia), (Ib), (Ic) and (Id) ##STR1## wherein: R.sup.1 and R.sup.2 are independently C.sub.1 -C.sub.10 alkyl;R.sup.3 is H or R.sup.4 wherein R.sup.4 is a hydroxy protecting group; andZ is H, --CHO, --C(O)OC(CH.sub.3).sub.3 or --C(O)OCH.sub.2 C.sub.6 H.sub.5.Also described is a process for preparing chiral hydrazines of the formula (Ia), (Ib), (Ic) and (Id).

Abstract: A method of inhibiting Ras function and therefore inhibiting cellular growth is disclosed. The method comprises the administration of a novel compound of the formula (Ia), (Ib) or (Ic) ##STR1## wherein: R and R.sup.1 are H, alkyl, halogeno, OH, alkoxy, NH.sub.2, alkylamino, dialkylamino, CF.sub.3, SO.sub.3 H, CO.sub.2 R.sub.3, NO.sub.2, SO.sub.2 NH.sub.2, or CONHR.sub.4 ;n is 0 or 1;R.sup.2 is a group of the formula R.sup.5 C(O)--, R.sup.5 CH.sub.2 C(O)--, R.sup.5 C(R.sup.6).sub.2 C(O)--, R.sup.5 SO.sub.2 --, R.sup.5 CH.sub.2 SO.sub.2 --, R.sup.5 SCH.sub.2 C(O)--, R.sup.5 OC(O)--, R.sup.5 NHC(O)--, R.sup.5 C(O)C(O)-- or R.sup.5 SC(O)--;R.sup.5 is alkyl, aryl, arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl or heterocycloalkyl; andR.sup.6 is alkyl or C(R.sup.6).sub.2 is a carbocyclic ring;or pharmaceutically acceptable salts thereof.

Abstract: Disclosed are a process and intermediates of the formulae ##STR1## wherein X.sup.- is halide, BF.sub.4.sup.-, R.sup.3 SO.sub.3.sup.-, wherein R.sup.3 is C.sub.1 -C.sub.6 alkyl, CF.sub.3, C.sub.1 -C.sub.6 alkylphenyl or phenyl, and Q is a group of the formula ##STR2## wherein R is C.sub.1 -C.sub.6 alkyl; useful for preparing benzazepine intermediates of the formula ##STR3## These benzazepine intermediates are useful for preparing benzazepines having activity as selective D1 receptor antagonists.